Sickle cell disease Market: Epidemiology, Therapies, Companies, DelveInsight | Global Blood Therapeutics, Pfizer, Agios Pharmaceuticals, Editas Medicine, Forma Therapeutics, Novo Nordisk, Bausch Health, Bluebird Bio

Sickle cell disease therapies, such as CASGEVY (exagamglogene autotemcel), ENDARI (L-glutamine), Mitapivat, Inclacumab, and others, are expected to boost the Sickle cell disease Market in the upcoming years.

DelveInsight has launched a new report on "Sickle cell disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Sickle cell disease, historical and forecasted epidemiology as well as the Sickle cell disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Sickle cell disease market report @ https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Sickle cell disease Market Report:

In 2023, the Sickle Cell Disease (SCD) market in the 6 major markets (6MM) was valued at approximately USD 650 million, with the US holding the largest share (~USD 603 million), followed by France and the UK. SCD is a genetic disorder caused by mutations in the HBB gene, leading to abnormal, sickle-shaped red blood cells that block blood flow and cause painful crises. It mainly affects populations of African, Middle Eastern, Mediterranean, and South Asian descent.
Common complications include anemia, organ damage, stroke, and infections. Current treatments include NSAIDs, blood transfusions, chelators, and FDA-approved drugs like hydroxyurea (DROXIA), L-glutamine (ENDARI), crizanlizumab (ADAKVEO), and voxelotor (OXBRYTA)-the first oral therapy targeting the disease's root cause.
Despite new therapies, challenges remain with treatment adherence and reimbursement. Recent FDA approvals of gene therapies CASGEVY (exa-cel) and LYFGENIA (Lovo-cel) promise to boost market growth. The pipeline includes emerging treatments like EDIT-301, Mitapivat, and Inclacumab.
Barriers such as delayed diagnosis, severe complications, economic burden, and limited awareness continue to impact the SCD market. Overall, ongoing advances and research offer hope for better management and potential cures, highlighting the need for improved healthcare services and patient support across the 6MM.
Several major companies, including Pfizer, Agios Pharmaceuticals, Editas Medicine, and Hoffmann-La Roche, are actively developing treatments for Sickle Cell Disease. The introduction of new and emerging therapies is expected to drive substantial market growth between 2024 and 2034. In 2023, the Sickle Cell Disease market in the 6MM was valued at around USD 650 million and is projected to expand further by 2034.
Approved in December 2023, Casgevy is the first FDA-approved CRISPR/Cas9 gene-editing therapy for SCD. It is indicated for patients aged 12 and older with recurrent vaso-occlusive crises. The therapy involves extracting a patient's hematopoietic stem cells, editing them to increase fetal hemoglobin production, and re-infusing them to reduce red blood cell sickling and related complications.
Key Sickle cell disease companies such as Global Blood Therapeutics, Pfizer, Agios Pharmaceuticals, Editas Medicine, Forma Therapeutics, Novo Nordisk, Bausch Health, Bluebird Bio, and others are evaluating new drugs for Sickle cell disease to improve the treatment landscape.
Promising Sickle cell disease therapies include CASGEVY (exagamglogene autotemcel), ENDARI (L-glutamine), Mitapivat, Inclacumab, and others.

Sickle cell disease Overview

Myositis refers to inflammation of the muscles and is commonly linked with a group of inflammatory muscle diseases, including polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). While *myositis* specifically involves inflammation, *myopathy* is a broader term encompassing any disease or disorder of the muscles, including but not limited to myositis.

This rare condition can impact not only the muscles but also various other organs, often resulting in significant reductions in quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases in which the immune system mistakenly attacks healthy muscle tissue. Dermatomyositis and polymyositis are the most frequently occurring types within this group.

Sickle cell disease Market Outlook

Sickle Cell Disease (SCD) is a group of inherited lifelong disorders affecting hemoglobin. It is a chronic hemolytic condition where hemoglobin molecules inside red blood cells polymerize, causing the cells to deform into a sickle or crescent shape (Hb S). This leads to vaso-occlusive events and increased breakdown of red blood cells.

SCD is classified as a large-vessel vasculitis but also affects medium and small arteries. It is inherited in an autosomal manner, either homozygous or compound heterozygous. When inherited homozygously, it is called sickle cell anemia (SCA). Other SCD genotypes include hemoglobin SC disease, sickle beta plus thalassemia, sickle beta zero thalassemia (similar in severity to SCA), hemoglobin SD Punjab, and hemoglobin SO Arab, among others. Hb S differs from normal hemoglobin (Hb A) by a single amino acid substitution in the beta-globin gene.

Newborn screening for Hb S is mandatory in the US. Infants are generally protected during the first six months by high levels of fetal hemoglobin (HbF). SCD symptoms typically appear early in childhood, with acute and chronic pain-especially vaso-occlusive crises-being the hallmark. These crises often cause severe bone pain due to bone marrow infarction.

Symptoms usually begin around four months of age, with painful episodes lasting hours to days, known as crises. Frequency varies, with some experiencing one episode per year and others many. These crises can be severe enough to require hospitalization, and all symptoms stem from reduced oxygen supply.

Discover how the Sickle cell disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Sickle cell disease marketed drugs
CASGEVY (exagamglogene autotemcel): Vertex Pharmaceuticals/CRISPR Therapeutics
ENDARI (L-glutamine): Emmaus Life Sciences

Sickle cell disease Emerging Drugs
Mitapivat: Agios Pharmaceuticals
Inclacumab: Pfizer

Scope of the Sickle cell disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Sickle cell disease Companies: Global Blood Therapeutics, Pfizer, Agios Pharmaceuticals, Editas Medicine, Forma Therapeutics, Novo Nordisk, Bausch Health, Bluebird Bio, and others
Key Sickle cell disease Therapies: CASGEVY (exagamglogene autotemcel), ENDARI (L-glutamine), Mitapivat, Inclacumab, and others
Sickle cell disease Therapeutic Assessment: Sickle cell disease current marketed and Sickle cell disease emerging therapies
Sickle cell disease Market Dynamics: Sickle cell disease market drivers and Sickle cell disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Sickle cell disease Unmet Needs, KOL's views, Analyst's views, Sickle cell disease Market Access and Reimbursement

To know what's more in our Sickle cell disease report, visit https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Sickle cell disease Market Report:
Sickle cell disease market report covers a descriptive overview and comprehensive insight of the Sickle cell disease Epidemiology and Sickle cell disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Sickle cell disease market report provides insights into the current and emerging therapies.
The Sickle cell disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Sickle cell disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Sickle cell disease market.

Got queries? Click here to know more about the Sickle cell disease market Landscape https://www.delveinsight.com/sample-request/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Sickle cell disease Patient Share (%) Overview at a Glance
5. Sickle cell disease Market Overview at a Glance
6. Sickle cell disease Disease Background and Overview
7. Sickle cell disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Sickle cell disease
9. Sickle cell disease Current Treatment and Medical Practices
10. Unmet Needs
11. Sickle cell disease Emerging Therapies
12. Sickle cell disease Market Outlook
13. Country-Wise Sickle cell disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Sickle cell disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Sickle cell disease Market Outlook 2034 https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Sickle cell disease Pipeline Insights, DelveInsight

"Sickle cell disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sickle cell disease market. A detailed picture of the Sickle cell disease pipeline landscape is provided, which includes the disease overview and Sickle cell disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.